Mecapure 50 Tablet contains Mercaptopurine 50 mg, an antimetabolite anticancer medicine widely used in the treatment of certain hematological malignancies, particularly acute lymphoblastic leukemia (ALL). It helps control the growth and multiplication of abnormal blood cells by interfering with DNA and RNA synthesis, thereby slowing disease progression. The tablet is prescribed under the supervision of oncology and hematology specialists as part of comprehensive cancer treatment protocols.

Mercaptopurine belongs to the class of purine analogs and works by disrupting the production of genetic material required for the growth and division of rapidly multiplying cancer cells. This action helps suppress the proliferation of abnormal cells and supports effective disease management. Its established clinical efficacy has made it an important component of maintenance therapy and long-term treatment strategies in selected hematological cancers.

The tablet is commonly used in the management of acute lymphoblastic leukemia and may also be prescribed for other hematological disorders as determined by a healthcare specialist. It is often utilized as part of combination treatment regimens to improve therapeutic outcomes and maintain disease control. Regular monitoring during therapy is essential to evaluate treatment response and minimize the risk of adverse effects associated with long-term use.

With the growing demand for specialized oncology and hematology treatments, Mecapure 50 Tablet maintains strong relevance in the anticancer segment. Its proven clinical utility, established role in leukemia management, and continued physician acceptance contribute to consistent market demand. The product offers valuable business opportunities and sustainable growth potential for retailers and distributors operating within the oncology pharmaceutical sector.

Mecapure 50 Tablet may cause nausea, vomiting, loss of appetite, abdominal discomfort, fatigue, weakness, mouth ulcers, and changes in liver function tests. Bone marrow suppression, anemia, low white blood cell counts, increased susceptibility to infections, and bleeding tendencies may occur and require close medical supervision.

Mecapure 50 Tablet is indicated for the treatment of acute lymphoblastic leukemia (ALL) and other hematological malignancies as determined by a healthcare specialist. It helps control abnormal cell growth and supports long-term disease management as part of comprehensive treatment protocols.

This medication should be used only under the supervision of a qualified healthcare professional experienced in oncology or hematology treatment. Regular monitoring of blood counts, liver function, and overall patient health is essential throughout therapy. Patients should promptly report fever, unusual bleeding, persistent fatigue, signs of infection, or any other concerning symptoms. Dosage adjustments may be required based on individual response and laboratory findings.

Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children. Do not use after the expiry date or if the packaging is damaged, opened, or shows signs of tampering.